Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | PYGL | P06737 | 2/20 | 0.38 |
| ▸ | PYGM | P11217 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23275075 | 0.84 | MTNR1A (0.46) | SMYD3MTNR1AGAAMAPTPTK2B | |
| SCHEMBL7954949 | 0.84 | SMYD3 (0.46) | SMYD3MTNR1AGAAMAPTPTK2B | |
| SCHEMBL28119251 | 0.78 | SMYD3 (0.44) | SMYD3MTNR1AGAAMAPTCA1 | |
| SCHEMBL8568355 | 0.77 | MTNR1A (0.50) | SMYD3MTNR1AGAAMTNR1BCA1 | |
| SCHEMBL8568359 | 0.77 | MTNR1A (0.50) | SMYD3MTNR1AGAAMTNR1BCA1 | |
| SCHEMBL8568363 | 0.77 | MTNR1A (0.50) | SMYD3MTNR1AGAAMTNR1BCA1 | |
| SCHEMBL1268909 | 0.76 | SMYD3 (0.59) | SMYD3MTNR1AGAAMAPTPTK2B | |
| SCHEMBL20870877 | 0.75 | PDPK1 (0.46) | SMYD3MTNR1AGAAMAPTMTNR1B | |
| SCHEMBL535128 | 0.74 | CYP3A4 (0.43) | SMYD3MTNR1AGAAMAPTMASP2 | |
| SCHEMBL5685869 | 0.72 | MTNR1A (0.57) | SMYD3MTNR1AGAAMAPTPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685112-B1 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VR1 ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | claimed |
| JP-2007523888-A | — | — | 2007-08-23 | — | — | JP | claimed |
| EP-1685112-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005044802-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VRL ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-05-19 | — | — | WO | claimed |
| US-4466967-A | NONTOXIC INSECTICIDES | ROHM AND HAAS COMPANY (US) | 1984-08-21 | — | — | US | claimed |
| US-4419360-A | UREA OR THIOUREA DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1983-12-06 | — | — | US | claimed |
| US-20230115534-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2023-04-13 | — | — | US | disclosed |
| WO-2021127303-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-1685112-B1 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VR1 ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| EP-1685112-B1 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VR1 ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2011-07-20 | — | — | EP | disclosed |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-03 | — | — | US | disclosed |
| US-20070213363-A1 | Tetrahydro-Quinolinylurea Derivatives | BAYER HEALTHCARE AG (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1685112-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1685112-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005044802-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VRL ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044802-A2 | TETRAHYDRO-QUINOLINYLUREA DERIVATIVES AS VRL ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2005-05-19 | — | — | WO | disclosed |
| US-4466967-A | NONTOXIC INSECTICIDES | ROHM AND HAAS COMPANY (US) | 1984-08-21 | — | — | US | disclosed |
| US-4419360-A | UREA OR THIOUREA DERIVATIVES | ROHM AND HAAS COMPANY (US) | 1983-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213363-A1 | Tetrahydro-Quinolinylurea Derivatives | NMUR1, OPRL1, NQO2 | SMYD3 4638/4885MTNR1A 91/4885GAA 2347/4885 |
| US-20100137361-A1 | Tetrahydro-Quinolinylurea Derivatives | NMUR1, OPRL1, HVCN1 | SMYD3 4452/4885MTNR1A 189/4885GAA 3048/4885 |
| US-20230115534-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | SMYD3 4658/4885MTNR1A 1749/4885GAA 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.